Unraveling the effects of glycerophosphoinositol-enriched hyaluronic acid eyedrops on the ocular surface in glaucoma: a report from the multicenter OSGLA registry
{{output}}
Purpose: To evaluate the effects of 0. 001% glycerophosphoinositol in 0.2% hyaluronate (GPI/HA) vehicle eye drops in patients with glaucoma therapy related-ocular surface disease (GTOSD). ... ...
